Sign Up
Stories
ARCA Biopharma Revenue Insights
Share
ABIO ARCA Revenue Analysis
ADR Surge and Drops in NY
ARCA Biopharma Revenue Insights
Amgen's Weight-Loss Drugs Market Entranc...
Analyst Recommendations Impact Diverse C...
Arcutis Biotherapeutics Initiates $150M ...
Overview
API
ABIO ARCA biopharma's revenue breakdown highlights Callida generating $612K and Nuvelo $54K. The stock boasts a P/E ratio of 14.50 and a 5.14% dividend yield.
Ask a question
How does the P/E ratio and dividend yield influence investor sentiment towards ABIO ARCA biopharma?
How might the revenue breakdown impact ARCA biopharma's strategic decisions?
What factors could explain the significant difference in revenue between Callida and Nuvelo?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Coverage
moomo
Feb